AbbVie, the biopharmaceutical company behind hepatitis C drug Viekira Pak, has reported its third quarter 2015 financial results.
Here are four things to know.
1. The company reported $5.944 billion in worldwide sales for the third quarter, an 18.4 percent year-over-year increase.
2. AbbVie's Viekira global sales for the quarter were $469 million. The HCV drug is now approved in 61 countries.
3. The company's net interest expense for the quarter was $197 million.
4. AbbVie's diluted earnings per share for the third quarter were $1.31, up approximately 27 percent.